Type 1 diabetes and chronic kidney disease can be treated with sotagliflozin, study indicates

Sotagliflozin treatment is beneficial for people living with type 1 diabetes and chronic kidney disease, latest research has shown.

Scientists have found that sotagliflozin added to insulin can reduce HbA1c, body weight and systolic blood pressure among those with type 1 diabetes chronic kidney disease (CKD).

In addition, sotagliflozin was associated with a lower risk of severe hypoglycaemia and did not significantly increase the risk of diabetic ketoacidosis (DKA).

During the trial, the team of researchers assessed the effects of sotagliflozin versus placebo on glycated hemoglobin, body weight, systolic blood pressure, insulin dose, and safety end points including adjudicated severe hypoglycemia and DKA, stratified by CKD.

The incidence of severe hypoglycemia was lower with sotagliflozin (seven per cent on 200 mg and four per cent on 400 mg) compared with placebo (17 per cent), the study has reported.

The research is available here.